Tapia Syndrome at the Time of the COVID-19 Pandemic
Neurol 95:312-313, Decavel, P.,et al, 2020
Steroid-Responsive Encephalitis in Coronavirus Disease 2019
Ann Neurol 88:423-427, Pilotto, A.,et al, 2020
A Young Generalized Dystonia Patient with Globus-Pallidus-Specific Lesion
Ann Neurol 88:637-638, Wu, H.,et al, 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Two Cases of Meningitis Associated with Ocrelizumab Therapy
Mult Scler Rel Dis 38:101866, Theriault, M. & Solomon, A.J., 2020
Fat Embolism Syndrome in Sickle Cell Disease
J Clin Med 9:1-12, Tsitsikas, D.A.,et al, 2020
A 70-year-old Man with Rapid Stepwise Paraparesis and Sensory Loss
Neurol 94:e651-e655, Krause, M.A.,et al, 2020
Management and Outcome of Primary CNS Lymphoma in the Modern Era
Neurol 94:e1027-e1039, Houillier, C., et al, 2020
Symptomatic Isolated Tongue Tremor of Cortical Origin Due to Stroke
Neurol 94:591-592, Thakolwiboon, S.,et al, 2020
Relapse of Severe Neurosarcoidosis with Switch from Originator Infliximab to Biosimilar
Neurol 94:991-993, Kidd, D.P.,et al, 2020
A 25-year-old Woman with Recurrent Episodes of Collapse and Loss of Consciousness
Neurol 94:994-999, Wildman, J.,et al, 2020
Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder (N-MOmentum): A Double-Blind, Randomised Placebo-Controlled Phase 2/3 Trial
Lancet 394:1352-1363,1304, Cree, B.A.C.,et al, 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Orofacial Dyskinesia in a Young Man
JAMA Neurol 76:1517-1518, Tian, X.,et al, 2019
GQ1b-Seronegative Miller Fisher Syndrome Associated with Pembrolizumab
J Neuro-Ophthal 39:394-396, Green, K.E.,et al, 2019
Delayed Complications of Cranial Irradiation
www.UptoDate.com, May, Dietrich, J.,et al, 2019
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
NEJM 381:132-141, Goadsby, P.J.,et al, 2019
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder
NEJM 381:614-625, Pittock, S.J.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Long-Term Safety and Efficacy of Eculizumab in Generalized Myasthenia Gravis
Muscle Nerve 60:14-24, Muppidi, S.,et al, 2019
MR Imaging of the Brain in Neurologic Wilson Disease
AJNR 40:178-183, Yu, X.-E.,et al, 2019
A 61-Year-Old Woman with Acute Onset Dysgraphia
Neurol 92:e386-e391, Smith, L.R.,et al, 2019
Simultaneous CMV and Listeria Infection Following Alemtuzumab Treatment for Multiple Sclerosis
Neurol 92:296-298, Pappolla, A.,et al, 2019
Clinicopathologic Conference, Ocular Syphilis
NEJM 380:1062-1071, Case 8-2019, 2019
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Clinicopathologic Conference, Amyotrophic Lateral Sclerosis
NEJM 380:1566-1574, Case 12-2019, 2019
Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy
NEJM 380:1597-1605, Cortese, I.,et al, 2019
A 23-Year-Old Man with Headaches, Confusion, and Lower Extremity Weakness
Neurol 92:863-867, Patel, N.M.,et al, 2019
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Behcet Disease
emedicine.medscape.com Dec, Davey-Ranasinghe, N. & Diamond, H.S., 2018
Progressive Multifocal Leukoencephalopathy: Epidemiology, Clinical Manifestations, and Diagnosis
www.UptoDate.com, May, Koralnik, I.J., 2018
Inflammatory Demyelinating Polyneuropathy Versus Leptomeningeal Disease Following Ipilimumab
J Immunother Cancer 6:11, Cafuir, L.,et al, 2018
Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
Emerg Inf Dis 24:1594-1596, Martinot, M.,et al, 2018
Nivolumab-Induced Autoimmune Encephalitis in Two Patients with Lung Adenocarcinoma
Case Rep Neurol Med 2018;doi:10.1155/2018/2548528, Shah, S.,et al, 2018
Bilateral Ageusia and Tongue Anesthesia Following Unilateral Brainstem Infarct: A Case Report with a Brief Review of the Literature
Case Rep Neurol 10:60-65, Saleh, C.,et al, 2018
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Deep Brain Nuclei T1 Shortening after Gadobenate Dimeglumine in Children: Influence of Radiation and Chemotherapy
AJNR 39:24-30, Kinner, S.,et al, 2018
Clinicopathologic Conference, Intracranial Hypertension Associated with Systemic Lupus Erythematosus and Steroid Use
NEJM 378:282-289, Case 2-2018, 2018
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Acute acalculous cholecystitis
Neurol 90:e1548-e1552, Croteau, D.,et al, 2018
A 77-year-old man presenting with episodic expressive aphasia
Neurol 90:e1822-e1826, Shanklin, A.,et al, 2018
A 41-year-old man with Thunderclap Headache
Neurol 91:e87-e91, Grossman, S.et al, 2018
Autoimmune Pancerebellitis Associated with Pembrolizumab Therapy
Neurol 91:91-93, Vitt, J.R.,et al, 2018
Treatable Bilateral Striatal Lesions Related to Anti-Dopamine 2 Receptor
Neurol 91:98-101, Marques-Matos, C.,et al, 2018
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Clnicopathologic Conference Anti-N-Methyl-D-Aspartate (NMDA) Receptor Encephalitis
NEJM 379:870-878, CASE 27-2018, 2018
Young Adult with Dysphagia and Severe Weight Loss
Neurol 91:e1083-e1086, Irumudomon, O. & Ghosh, P.S., 2018
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Distinctive Imaging in a Paucisymptomatic Child with Leukodystrophy
Neruol 91:e1368-e1369, Sharawat, I.K.,et al, 2018